MDS

Agios Appoints Rahul Ballal and Cynthia Smith to Board of Directors

Retrieved on: 
Monday, August 15, 2022 - 1:00pm

Agios is committed to assembling a top-notch, diverse board dedicated to realizing the companys long-term success and creating value for patients, shareholders, our team and all our stakeholders, said Brian Goff, chief executive officer of Agios.

Key Points: 
  • Agios is committed to assembling a top-notch, diverse board dedicated to realizing the companys long-term success and creating value for patients, shareholders, our team and all our stakeholders, said Brian Goff, chief executive officer of Agios.
  • Rahul and Cynthia are seasoned biopharmaceutical executives with critical expertise to help us maximize Agios potential.
  • He has served as Imaras president and chief executive officer and a member of the board of directors since June 2018.
  • Dr. Ballal joined Imara from Northern Biologics, where he served as chief business officer, and Versant Ventures, where he served as an entrepreneur-in-residence.

Roivant Sciences Reports Financial Results for the First Quarter Ended June 30, 2022 and Provides Business Update

Retrieved on: 
Monday, August 15, 2022 - 12:00pm

First Quarter Ended June 30, 2022 Financial Summary

Key Points: 
  • First Quarter Ended June 30, 2022 Financial Summary
    As of June 30, 2022, we had cash, cash equivalents and restricted cash of approximately $2.0 billion.
  • Net loss was $353.8 million for the three months ended June 30, 2022 compared to $101.1 million for the three months ended June 30, 2021.
  • On a per common share basis, net loss was $0.48 for the three months ended June 30, 2022 and $0.13 for the three months ended June 30, 2021.
  • Non-GAAP net loss was $210.7 million for the three months ended June 30, 2022 compared to $133.4 million for the three months ended June 30, 2021.

Jasper Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

Retrieved on: 
Friday, August 12, 2022 - 9:05pm

Research and Development (R&D) Expenses: R&D expenses for the quarter ended June 30, 2022 were $8.1 million compared to $5.2 million for the corresponding quarter in 2021.

Key Points: 
  • Research and Development (R&D) Expenses: R&D expenses for the quarter ended June 30, 2022 were $8.1 million compared to $5.2 million for the corresponding quarter in 2021.
  • If any of these risks materialize or Jasper Therapeutics assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements.
  • There may be additional risks that Jasper Therapeutics does not presently know, or that Jasper Therapeutics currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements.
  • While Jasper Therapeutics may elect to update these forward-looking statements at some point in the future, Jasper Therapeutics specifically disclaims any obligation to do so.

Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations

Retrieved on: 
Thursday, August 11, 2022 - 9:15pm

BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc.(Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways today reported financial results for the three and six months ended June 30, 2022 and provided a business update.

Key Points: 
  • BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc.(Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways today reported financial results for the three and six months ended June 30, 2022 and provided a business update.
  • Research and Development (R&D) expenses: R&D expenses were$6.8 millionfor the quarter endedJune 30, 2022, compared to$6.7 millionfor the comparable period in 2021.
  • General and Administrative (G&A) expenses: G&A expenses were$15.6 millionfor the quarter endedJune 30, 2022, compared to$3.3 millionfor the comparable period in 2021.
  • Acquired In-Process Research and Development (IPR&D) expenses: Acquired IPR&D expense was $76.0 million for the quarter ended June 30, 2022.

Geron Corporation Reports Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 11, 2022 - 9:05pm

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results for the second quarter of 2022 and key upcoming expected milestones.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results for the second quarter of 2022 and key upcoming expected milestones.
  • Assuming positive top-line results, U.S. and EU regulatory submissions are also planned in the first and second half of 2023, respectively.
  • ET on Thursday, August 11, 2022 to review recent events and second quarter 2022 financial results.
  • Geron encourages investors to carefully consider the Companys results under GAAP, as well as the supplemental non-GAAP financial information, to more fully understand Gerons business.

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Retrieved on: 
Wednesday, August 10, 2022 - 12:00pm

CAMBRIDGE, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapeutic candidates across multiple modalities for patients with cancer, today reported on recent and upcoming business highlights and announced its financial results for the second quarter ended June 30, 2022.

Key Points: 
  • In collaboration with its partner, Taiho Oncology, Cullinan Oncology intends to initiate a pivotal study for CLN-081 in the second half of 2022 under the co-development agreement.
  • During the second quarter of 2022, we received cash proceeds of $270 million from the sale of Cullinan Pearl.
  • R&D Expenses: Research and development (R&D) expenses were $26.4 million for the second quarter of 2022, compared to $24.5 million for the first quarter of 2022.
  • G&A Expenses: General and administrative (G&A) expenses were $10.7 million for the second quarter of 2022, compared to $8.1 million for the first quarter of 2022.

Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update

Retrieved on: 
Tuesday, August 9, 2022 - 12:00pm

CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today provided a financial and corporate update in conjunction with the Company’s 10-Q filing for the quarter ended June 30, 2022. With an initial focus in oncology, Foghorn’s Gene Traffic Control® Platform and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases.

Key Points: 
  • Collaboration revenues were $4.5 million for the second quarter of 2022 compared to $0.3 million the second quarter of 2021.
  • Research and Development Expenses.Research and development expenses were $26.0 million for the second quarter of 2022 compared to $18.6 million for the second quarter of 2021.
  • General and Administrative Expenses.General and administrative expenses were $7.7 million for the second quarter of 2022, compared to $4.9 million for the second quarter of 2021.
  • Net Loss.Net loss was $27.3 million for the second quarter of 2022 compared to a net loss of $23.1 million for the second quarter of 2021.

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Executive Officer

Retrieved on: 
Monday, August 8, 2022 - 11:36pm

The grants were approved by the board of directors effective as of August 8, 2022 as inducements material to Mr. Goff entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The grants were approved by the board of directors effective as of August 8, 2022 as inducements material to Mr. Goff entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The inducement grants consisted of (i) a nonstatutory option to purchase up to 561,083 shares of common stock, (ii) restricted stock units for 68,073 shares of common stock and (iii) performance stock units for 170,183 shares of common stock.
  • The option has an exercise price of $29.38 per share, the closing price per share of the companys common stock as reported by Nasdaq on August 8, 2022.
  • Each restricted stock unit will entitle Mr. Goff to receive one share of the companys common stock for each restricted stock unit that vests.

FibroGen Reports Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022 - 9:01pm

2Q 2022 revenue of $29.8 million, growth of 22% vs. 2Q 2021

Key Points: 
  • 2Q 2022 revenue of $29.8 million, growth of 22% vs. 2Q 2021
    SAN FRANCISCO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the second quarter 2022 and provided an update on the companys recent developments.
  • Second quarter total roxadustat net sales in China1 by FibroGen and the distribution entity (JDE) jointly owned by FibroGen and AstraZeneca was $53.1 million, compared to $52.8 million in the second quarter of 2021.
  • Total revenue for the second quarter of 2022 was $29.8 million, as compared to $24.4 million for the second quarter of 2021.
  • FibroGen will host a conference call and webcast today, Monday, August 8, 2022, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss financial results and provide a business update.

Netsmart Announces the Skilled Nursing Industry’s Only Data Analytics Solution with a Complete View of Claims, MDS and Staffing

Retrieved on: 
Monday, August 8, 2022 - 6:00pm

Netsmart announced today it has acquired CORE Analytics , the industry-leading skilled nursing facility (SNF) claims data analytics offering from Zimmet Healthcare.

Key Points: 
  • Netsmart announced today it has acquired CORE Analytics , the industry-leading skilled nursing facility (SNF) claims data analytics offering from Zimmet Healthcare.
  • With the addition of Core Analytics, Netsmart Simple is now the only solution suite in the market capable of calculating quality measures and Five-Star ratings leveraging Minimum Data Set (MDS), Payroll-Based Journaling (PBJ) and UB-04 claims data.
  • The Netsmart and CORE teams share a mutual dedication to providing data solutions to inform and equip business decisions, said Netsmart CEO Mike Valentine.
  • This commonality of values will further scale the Netsmart data suite to better support and help skilled nursing facilities thrive with transforming payment models.